Idorsia Pharmaceuticals Ltd: Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as
Source: finanznachrichten.de